Desara ® One Single Incision Sling 522 Study

Stress Urinary Incontinence Clinical Trial

Official title:

Prospective, Post-market Study of the Desara® One Single Incision Sling vs. Desara® Blue Sling Implanted Via the Transobturator Route for the Treatment of Women With Stress Urinary Incontinence

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04772131
• Other study ID #: PS200005
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2021
• Est. completion date: November 2026

Study information

• Verified date: October 2023
• Source: Caldera Medical, Inc.
• Contact: Vicki Gail
• Phone: 818-483-7602
• Email: vgail[@]calderamedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A post-market study to compare the safety and effectiveness of the Desara® One Single Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a period of 36 months.

Description:

This study is a prospective, non-randomized, parallel cohort, multi-center study of Desara® One single incision sling (SIS) compared to Desara® Blue sling systems implanted via the transobturator-route (TOR) for the treatment of women with stress urinary incontinence (SUI). The study will compare results from SIS patients (N=150) and TOR patients (N=150) at up to 40 sites for a total period of 36 months, with follow-up visits at 2 and 6 weeks, 6, 12, 18, 24 and 36 months. This study will enroll adult females who are clinically indicated for a mid-urethral implant for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: November 2026
• Est. primary completion date: November 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female = 18 of age.

2. Subject agrees that she is willing and able to return for all study related procedures and evaluations.

3. Subject has provided signed informed consent.

4. Subject has stress urinary incontinence (SUI) confirmed by either supine or standing cough stress test (CST) with bladder pre-fill to subjective fullness with 200-300 mL, or with bladder fullness confirmed via ultrasound.

5. Subject has confirmed stress incontinence greater than urge incontinence per MESA questionnaire.

6. Subject no longer has childbearing capacity or has a negative pregnancy test and has decided to cease childbearing. Childbearing capacity to be confirmed by documented history of:

1. A hysterectomy or

2. Tubal ligation or

3. Is otherwise incapable of pregnancy or has

4. Negative pregnancy test prior to study entry and has decided to cease childbearing

7. Subject has been offered and either failed or refused alternative non-invasive SUI treatment options and has elected to proceed with a surgical intervention.

8. Subject is eligible to undergo laparoscopic/robotic (with or without mesh) or vaginal (with or without mesh) apical, anterior or posterior prolapse concomitant surgical repair procedures (non-mesh).

Exclusion criteria:

1. Subject reports baseline pelvic pain = 2 on 10 point Numeric Rating Scale (NRS).

2. Subject has a known neurological disease (with or without signs/symptoms of neurogenic bladder).

3. Subject has known pre-existing pain syndrome and/or has been evaluated by an interventional pain management physician.

4. Subject has a history of chronic opioid, or narcotic use for:

1. pain or

2. any other specified reason

5. Subject is on anti-coagulation therapy that cannot be suspended or adjusted for a minimum of 24-48 hours prior to planned sling implantation surgery.

6. Subject is on chronic (> 3 months) systemic steroid treatment (except for inhalational use as indicated for pulmonary conditions).

7. Subject has uncontrolled diabetes defined as A1c = 7% or fasting serum glucose > 130mg/dl at screening/baseline.

8. Subject has an active lesion or skin infection of the perineum, urethra, or vagina as noted per visual pelvic exam.

9. Subject has active UTI which requires treatment, as determined by the Investigator.

10. Subject has pattern of recurrent UTIs, defined as = 3 culture-proven UTIs during the 6-month period prior to surgery.

11. Subject has a urethral obstruction or other anatomic defects of the urethra (inclusive of urethral diverticulum or stricture or bladder neck contracture).

12. The subject has had:

1. any prior surgical stress urinary incontinence treatment or

2. any prior surgery on their urethra or

3. any prior surgery to distal anterior vaginal wall, including fistula repair or prior cystocele repair

4. any previous pelvic floor mesh use or complication

13. Subject has any of the following confounding conditions:

1. bladder stones or tumors

2. pathology that in the opinion of the Investigator would compromise implant placement

3. pathology that would limit pelvic blood supply

4. pathology that would require chemotherapy and systemic use of immunosuppressants

14. Subject has abnormal bladder capacity <300 mL.

15. Subject has a post void residual volume = 150 mL on two different measurements. (Prolapse reduction during PVR measurement is only allowed if a prolapse repair will be performed concomitantly with the sling implantation)

16. Subject has had previous radiation therapy or brachytherapy to the pelvis.

17. Subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function, interfere with clinical outcomes, or impact analysis of this device.

18. Subject has known reaction, sensitivity or allergy to polypropylene.

Related Conditions & MeSH terms

• Enuresis
• Stress Urinary Incontinence
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• Desara® One Single Incision Sling
Single incision sling
• Desara® Blue Transobturator Sling
Standard mid-urethral sling

Locations

Country	Name	City	State
United States	University of New Mexico	Albuquerque	New Mexico
United States	Mt. Auburn Hospital Division of Urogynecology	Cambridge	Massachusetts
United States	Novant Health Urogynecology	Charlotte	North Carolina
United States	The Lindner Research Center at The Christ Hospital	Cincinnati	Ohio
United States	Center for Pelvic Health	Franklin	Tennessee
United States	Urological Research Center Corp	Hialeah	Florida
United States	Women's Health Care Associates P.A. dba Rosemark Women Care Specialists	Idaho Falls	Idaho
United States	Center for Total Women's Health	Lansdale	Pennsylvania
United States	Women's Cancer Center of Nevada	Las Vegas	Nevada
United States	University of Louisville	Louisville	Kentucky
United States	CMB Research, LLC	Newburgh	Indiana
United States	Valley Urogynecology Associates, Inc.	Phoenix	Arizona
United States	Specialty Clinical Research of St. Louis, LLC	Saint Louis	Missouri
United States	University of Washington Medical Center	Seattle	Washington
United States	University of Arizona College of Medicine	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Caldera Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success rate of negative standing cough stress test (CST)	Negative standing cough stress test (CST) with bladder pre-fill to subjective fullness with 200-300 mL, or with bladder fullness confirmed via ultrasound, evaluated at the 36-month post-implant follow-up visit. The success rate is defined as the proportion of subjects with a negative CST at the 36-month post-implant follow-up	36 months
Primary	Device and Procedure-related serious adverse events	Device- and/or procedure-related adverse event rates at the post-implant follow-up visits; Revision/re-surgery rates at post-implant follow-up visits; Device and/or procedure-related serious adverse events	36 months
Secondary	Composite outcome success rates	Defined by the primary effectiveness endpoint and subjective measure of Improvement in the Patient Global Impression of Improvement (PGI-I) index for incontinence post-implant	6 weeks, 6, 12, 18, 24, 36 months
Secondary	Sexual Function Assessment	Use of PISQ-12: Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire to assess subject changes in sexual function	6 weeks, 6, 12, 18, 24, 36 months
Secondary	Improvement in Incontinence	Use of PGI-I: Patients Global Impression of Improvement index for incontinence to assess subject improvement post-implant	6 weeks, 6, 12, 18, 24, 36 months
Secondary	Improvement in Urinary Symptoms	Use of IIQ-7: Incontinence Impact Questionnaire, Short Form and ICIQ-UI: International Consultation on Incontinence Questionnaire-Urinary Incontinence to assess improvement in urinary symptoms post-implant	6 weeks, 6, 12, 18, 24, 36 months
Secondary	Improvement in Urge and Stress Incontinence	Use of UDI-6 SF: Urinary Distress Inventory, Short Form to assess subject improvement in urge and stress incontinence post-implant	6 weeks, 6, 12, 18, 24, 36 months
Secondary	Subject pain assessment	Use of Numeric Rating 10-point scale (NRS) to assess post-operative pain. Pain scale is 0= no pain to 10 = worst pain	6 weeks, 6, 12, 18, 24, 36 months
Secondary	Time to void post-implant	Perform a standard post void residual test to confirm that the subject's residual urine volume is =150 mL	6 weeks, 6, 12, 18, 24, 36 months